The World Health Organization's (WHO's) Choosing Interventions that are Cost-Effective (CHOICE) programme has been a global leader in the field of economic evaluation, specifically cost-effectiveness analysis for almost 20 years. WHO-CHOICE takes a "generalized" approach to cost-effectiveness analysis that can be seen as a quantitative assessment of current and future efficiency within a health system. This supports priority setting processes, ensuring that health stewards know how to spend resources in order to achieve the highest health gain as one consideration in strategic planning. This approach is unique in the global health landscape. This paper provides an overview of the methodological approach, updates to analytic framework over the past 10 years, and the added value of the WHO-CHOICE approach in supporting decision makers as they aim to use limited health resources to achieve the Sustainable Development Goals (SDGs) by 2030.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278384 | PMC |
| http://dx.doi.org/10.34172/ijhpm.2020.244 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Valuing the benefits of reducing firearm violence in the United States.
Proc Natl Acad Sci U S A
January 2025
Harris School of Public Policy, University of Chicago, Chicago, IL 60637.
Justifying a proposed government regulation intended to reduce firearm violence requires a conceptually sound estimate of the monetized value of that impact and how that value is distributed across the population. Some previous estimates do not serve as a valid basis for policy evaluation or are out of date. A nationally representative survey was conducted by the AP-NORC Center for Public Affairs Research in August 2022 (n = 660).
View Article and Find Full Text PDFEconomic evaluation in the treatment of unruptured intracranial aneurysms in the Swiss healthcare system: a retrospective cost evaluation.
Swiss Med Wkly
December 2024
Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.
The choice of modality of treatment for unruptured intracranial aneurysms is based on various clinical aspects and the patient's preference. Financial considerations should not be among these. To evaluate any financial variations between endovascular and microsurgical treatment of unruptured intracranial aneurysms in the Swiss healthcare system, we retrospectively reviewed 100 consecutive aneurysm cases treated as inpatients in our institution.
View Article and Find Full Text PDFInduced Sputum: A Valuable Tool for Assessing Cellular and Microbiological Characteristics in Cystic Fibrosis Expectorating Teenagers.
Pediatr Pulmonol
January 2025
Centre de Ressources et de Compétences pour la Mucoviscidose, CHU Timone-Enfants, Marseille, France.
Introduction: Cellular characteristics of induced sputum (IS) are not investigated in cystic fibrosis (CF) patients.
Objectives: This pilot study, conducted on 17 expectorating CF adolescents, compared sputa obtained the same day, in a stable period, by autogenic drainage (expectorating sputum, ES) and 4 h later after inhaling hypertonic saline (IS).
Results: No difference was noted concerning weight, volume, and percentage of dead cells between the two collection methods.
A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland.
Swiss Med Wkly
January 2025
Cancer Center und Research Center, Cantonal Hospital Graubünden, Chur, Switzerland.
Background And Objective: Because of the lack of effective targeted treatment options, docetaxel has long been the standard second-line therapy for patients with advanced non-small cell lung cancer, including the Kirsten rat sarcoma virus (KRAS) G12C mutation. The CodeBreak 200 trial demonstrated that sotorasib, a new drug targeting the G12C-mutated KRAS protein, modestly improved progression-free survival compared with docetaxel in patients whose cancer had progressed after receiving platinum chemotherapy and programmed cell death protein 1 (PD-1) / programmed death ligand 1 (PD-L1) inhibitors as first-line treatment. Consequently, sotorasib received temporary approval in Switzerland.
View Article and Find Full Text PDFHow do children with Cerebral Visual Impairment (CVI)-related visual difficulties perform on key academic domains in grade 1?
Child Neuropsychol
January 2025
Luxembourg Centre for Educational Testing, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Previous research estimated a prevalence of 3.4% Cerebral Visual Impairment (CVI)-related visual problems within primary school children, potentially compromising students' performance. This study aimed to clarify how CVI-related visual difficulties relate to academic performance in standardized achievement tests.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!